Product Development

Product Development


Inflammation / Autoimmune Disease

Midkine neutralizing antibodies reduce inflammatory leukocyte recruitment to inflamed tissue, reduce NETosis of neutrophils, induce B cell apoptosis and induce Regulatory T-cell expansion, bringing together important properties that support treatment of inflammation and auto-immune disease. Midkine antibodies also protect vital organs from fibrosis .


Inflammatory bone disease

Midkine neutralising antibodies induce osteoblast activity via the Wnt pathway, increasing bone mass and quality in post-menopausal osteoporosis. In addition, midkine antibodies reduce fracture related inflammation and accelerate fracture healing, which is particularly important in elderly patients with chronic fracture-related inflammation and osteoporosis.


Cardiovascular disease

Midkine contributes to many aspects of atherosclerosis and midkine blocking antibodies may reduce inflammatory cell recruitment to atherosclerotic plaques, reduce conversion of macrophages to foam cells, reduce neointima formation and reduce migration and calcification of vascular smooth muscle cells. In chronic heart failure, midkine antibodies may reduce inflammation and protect against fibrosis and loss of heart function.


Midkine as Diagnostic Biomaker

Lyramid markets a highly specific midkine ELISA kit (MK-ELISA) to measure midkine levels in blood and urine of patients. This kit has been used to validate midkine as an informative diagnostic, prognostic and predictive biomarker for several tumour types including prostate, glioma, melanoma, thyroid, mesothelioma B-cell malignancies and GI tumours.

Midkine has been validated as a marker of disease progression in large cohorts of patients with autoimmune diseases, cancer, osteoporosis, CKD and vascular disease.

The midkine targeted products of Lyramid are protected by an extensive portfolio of patents, including composition of matter and patents that cover therapeutic use in specific indications.